SEARCH:   Advanced

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Furlan, M Articles by Lamie, B Search for Related Content PubMed PubMed Citation Articles by Furlan, M Articles by Lamie, B Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis M Furlan, R Robles and B Lamie Central Hematology Laboratory of the University, Inselspital, Bern, Switzerland. Proteolytic cleavage of von Willebrand factor (vWF) takes place in the circulating blood of healthy subjects and is increased in some patients with von Willebrand disease type 2A. The hemostatically active large vWF multimers are degraded to smaller less active forms. It has been suggested that the polypeptide subunit of vWF is cleaved at the peptide bond 842Tyr-843Met. We purified (approximately 10,000-fold) from human plasma a vWF-degrading protease, using chelating Sepharose, hydrophobic interaction chromatography, and gel filtration. The enzyme was found to be virtually absent in the platelet lysates obtained by repeated freezing and thawing. The proteolytic activity was associated with a high molecular weight protein (approximately 300 kD) as judged by gel filtration and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. vWF was resistant against the protease in a neutral buffer at physiological ionic strength but became degraded at low salt concentration or in the presence of 1 mol/L urea. No degradation of human fibrinogen, bovine serum albumin, of calf skin collagen by the purified protease was noted under the same experimental conditions. Proteolytic activity showed a pH optimum at 8 to 9 and was strongly inhibited by chelating agents, whereas only slow inhibition was observed with N-ethylmaleimide. There was no inhibition by iodoacetamide, leupeptin, or serine protease inhibitors. The best peptidyl diazomethyl ketone inhibitor was Z-Phe-Phe-CHN2. Activation by divalent metal ions was found to increase in the following order: Zn2+ approximately Cu2+ approximately CD2+ approximately Ni2+ approximately Co2+ <Mn2+ <Mg2+ <Ca2+ <Sr2+ <Ba2+. The observed properties of the vWF- degrading enzyme differ from those of all other hitherto described proteases. Purified vWF was incubated with the protease, and the degraded material subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis after disulfide reduction. The size, amino acid composition, and amino terminal sequence of the reduced fragments confirmed that the peptide bond 842Tyr-843Met had been cleaved, ie, the same bond that has been proposed to be cleaved in vivo. Volume 87, Issue 10, pp. 4223-4234, 05/15/1996 Copyright © 1996 by The American Society of Hematology CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. B. Feys, I. Pareyn, R. Vancraenenbroeck, M. De Maeyer, H. Deckmyn, C. Van Geet, and K. Vanhoorelbeke Mutation of the H-bond acceptor S119 in the ADAMTS13 metalloprotease domain reduces secretion and substrate turnover in a patient with congenital thrombotic thrombocytopenic purpura Blood, November 19, 2009; 114(21): 4749 - 4752. [Abstract] [Full Text] [PDF] M. Akiyama, S. Takeda, K. Kokame, J. Takagi, and T. Miyata Crystal structures of the noncatalytic domains of ADAMTS13 reveal multiple discontinuous exosites for von Willebrand factor PNAS, November 17, 2009; 106(46): 19274 - 19279. [Abstract] [Full Text] [PDF] F. Yu, Y. Tan, and M.-H. Zhao Lupus nephritis combined with renal injury due to thrombotic thrombocytopaenic purpura-haemolytic uraemic syndrome Nephrol. Dial. Transplant., August 23, 2009; (2009) gfp421v1. [Abstract] [Full Text] [PDF] T. J. Raife, W. Cao, B. S. Atkinson, B. Bedell, R. R. Montgomery, S. R. Lentz, G. F. Johnson, and X. L. Zheng Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site Blood, August 20, 2009; 114(8): 1666 - 1674. [Abstract] [Full Text] [PDF] X. Zhang, K. Halvorsen, C.-Z. Zhang, W. P. Wong, and T. A. Springer Mechanoenzymatic Cleavage of the Ultralarge Vascular Protein von Willebrand Factor Science, June 5, 2009; 324(5932): 1330 - 1334. [Abstract] [Full Text] [PDF] Y. Abe, H. Wada, E. Yamada, M. Noda, M. Ikejiri, J. Nishioka, T. Kobayashi, T. Matsumoto, M. Masuya, S. Isaji, et al. The Effectiveness of Measuring for Fragmented Red Cells Using an Automated Hematology Analyzer in Patients With Thrombotic Microangiopathy Clinical and Applied Thrombosis/Hemostasis, June 1, 2009; 15(3): 257 - 262. [Abstract] [PDF] R. de Groot, A. Bardhan, N. Ramroop, D. A. Lane, and J. T. B. Crawley Essential role of the disintegrin-like domain in ADAMTS13 function Blood, May 28, 2009; 113(22): 5609 - 5616. [Abstract] [Full Text] [PDF] P. Laje, D. Shang, W. Cao, M. Niiya, M. Endo, A. Radu, N. DeRogatis, F. Scheiflinger, P. W. Zoltick, A. W. Flake, et al. Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy Blood, March 5, 2009; 113(10): 2172 - 2180. [Abstract] [Full Text] [PDF] J. Huang, R. Roth, J. E. Heuser, and J. E. Sadler Integrin {alpha}v{beta}3 on human endothelial cells binds von Willebrand factor strings under fluid shear stress Blood, February 12, 2009; 113(7): 1589 - 1597. [Abstract] [Full Text] [PDF] M. D. Gardner, C. K. N. K. Chion, R. de Groot, A. Shah, J. T. B. Crawley, and D. A. Lane A functional calcium-binding site in the metalloprotease domain of ADAMTS13 Blood, January 29, 2009; 113(5): 1149 - 1157. [Abstract] [Full Text] [PDF] I. Garagiola, C. Valsecchi, S. Lavoretano, H. Oren, M. Bohm, and F. Peyvandi Nonsense-mediated mRNA decay in the ADAMTS13 gene caused by a 29-nucleotide deletion Haematologica, November 1, 2008; 93(11): 1678 - 1685. [Abstract] [Full Text] [PDF] S. Lancellotti, S. Rutella, V. De Filippis, N. Pozzi, B. Rocca, and R. De Cristofaro Fibrinogen-elongated {gamma} Chain Inhibits Thrombin-induced Platelet Response, Hindering the Interaction with Different Receptors J. Biol. Chem., October 31, 2008; 283(44): 30193 - 30204. [Abstract] [Full Text] [PDF] M. S. Buzza, J. M. Dyson, H. Choi, E. E. Gardiner, R. K. Andrews, D. Kaiserman, C. A. Mitchell, M. C. Berndt, J.-F. Dong, and P. I. Bird Antihemostatic Activity of Human Granzyme B Mediated by Cleavage of von Willebrand Factor J. Biol. Chem., August 15, 2008; 283(33): 22498 - 22504. [Abstract] [Full Text] [PDF] J. E. Sadler Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura Blood, July 1, 2008; 112(1): 11 - 18. [Abstract] [Full Text] [PDF] W. Cao, S. Krishnaswamy, R. M. Camire, P. J. Lenting, and X. L. Zheng Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13 PNAS, May 27, 2008; 105(21): 7416 - 7421. [Abstract] [Full Text] [PDF] M.-C. Chung, T. G. Popova, S. C. Jorgensen, L. Dong, V. Chandhoke, C. L. Bailey, and S. G. Popov Degradation of Circulating von Willebrand Factor and Its Regulator ADAMTS13 Implicates Secreted Bacillus anthracis Metalloproteases in Anthrax Consumptive Coagulopathy J. Biol. Chem., April 11, 2008; 283(15): 9531 - 9542. [Abstract] [Full Text] [PDF] T. A. J. McKinnon, A. C. K. Chion, A. J. Millington, D. A. Lane, and M. A. Laffan N-linked glycosylation of VWF modulates its interaction with ADAMTS13 Blood, March 15, 2008; 111(6): 3042 - 3049. [Abstract] [Full Text] [PDF] B. Lammle, J. A. Kremer Hovinga, and J. N. George Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease Haematologica, February 1, 2008; 93(2): 172 - 177. [Full Text] [PDF] K. C. Desch and D. G. Motto Thrombotic Thrombocytopenic Purpura in Humans and Mice Arterioscler Thromb Vasc Biol, September 1, 2007; 27(9): 1901 - 1908. [Abstract] [Full Text] [PDF] P. M. Mannucci Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome: much progress and many remaining issues Haematologica, July 1, 2007; 92(7): 878 - 880. [Full Text] [PDF] K. K. Swisher, J. T. Doan, S. K. Vesely, H. C. Kwaan, B. Kim, B. Lammle, J. A. Kremer Hovinga, and J. N. George Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports Haematologica, July 1, 2007; 92(7): 936 - 943. [Abstract] [Full Text] [PDF] J. A. Davies, P. W. Collins, L. S. Hathaway, and D. J. Bowen Effect of von Willebrand factor Y/C1584 on in vivo protein level and function and interaction with ABO blood group Blood, April 1, 2007; 109(7): 2840 - 2846. [Abstract] [Full Text] [PDF] A. K. Chauhan, J. Kisucka, C. B. Lamb, W. Bergmeier, and D. D. Wagner von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins Blood, March 15, 2007; 109(6): 2424 - 2429. [Abstract] [Full Text] [PDF] J. N. George Evaluation and Management of Patients With Thrombotic Thrombocytopenic Purpura J Intensive Care Med, March 1, 2007; 22(2): 82 - 91. [Abstract] [PDF] C. K. N. K. Chion, C. J. M. Doggen, J. T. B. Crawley, D. A. Lane, and F. R. Rosendaal ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men Blood, March 1, 2007; 109(5): 1998 - 2000. [Abstract] [Full Text] [PDF] J. A. Davies and D. J. Bowen An association between the L1565 variant of von Willebrand factor and susceptibility to proteolysis by ADAMTS13 Haematologica, February 1, 2007; 92(2): 240 - 243. [Abstract] [Full Text] [PDF] T. C. Nguyen, A. Liu, L. Liu, C. Ball, H. Choi, W. S. May, K. Aboulfatova, A. L. Bergeron, and J.-f. Dong Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis Haematologica, January 1, 2007; 92(1): 121 - 124. [Abstract] [Full Text] [PDF] P. M. Mannucci and F. Peyvandi TTP and ADAMTS13: When Is Testing Appropriate? Hematology, January 1, 2007; 2007(1): 121 - 126. [Abstract] [Full Text] [PDF] K. K. Francis, N. Kalyanam, D. R. Terrell, S. K. Vesely, and J. N. George Disseminated Malignancy Misdiagnosed as Thrombotic Thrombocytopenic Purpura: A Report of 10 Patients and a Systematic Review of Published Cases Oncologist, January 1, 2007; 12(1): 11 - 19. [Abstract] [Full Text] [PDF] W. Gao, P. J. Anderson, E. M. Majerus, E. A. Tuley, and J. E. Sadler Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease PNAS, December 12, 2006; 103(50): 19099 - 19104. [Abstract] [Full Text] [PDF] J.-J. Wu, K. Fujikawa, B. A. McMullen, and D. W. Chung Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor PNAS, December 5, 2006; 103(49): 18470 - 18474. [Abstract] [Full Text] [PDF] R. De Cristofaro, F. Peyvandi, L. Baronciani, R. Palla, S. Lavoretano, R. Lombardi, E. Di Stasio, A. B. Federici, and P. M. Mannucci Molecular Mapping of the Chloride-binding Site in von Willebrand Factor (VWF): ENERGETICS AND CONFORMATIONAL EFFECTS ON THE VWF/ADAMTS-13 INTERACTION J. Biol. Chem., October 13, 2006; 281(41): 30400 - 30411. [Abstract] [Full Text] [PDF] A. Casonato, F. Fabris, E. Pontara, M. G. Cattini, N. Zocca, L. Gallinaro, A. Girolami, and A. Pagnan Diagnosis and Follow-up of Thrombotic Thrombocytopenic Purpura by Means of von Willebrand Factor Collagen Binding Assay Clinical and Applied Thrombosis/Hemostasis, July 1, 2006; 12(3): 296 - 304. [Abstract] [PDF] F. Banno, K. Kokame, T. Okuda, S. Honda, S. Miyata, H. Kato, Y. Tomiyama, and T. Miyata Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura Blood, April 15, 2006; 107(8): 3161 - 3166. [Abstract] [Full Text] [PDF] A. K. Chauhan, D. G. Motto, C. B. Lamb, W. Bergmeier, M. Dockal, B. Plaimauer, F. Scheiflinger, D. Ginsburg, and D. D. Wagner Systemic antithrombotic effects of ADAMTS13 J. Exp. Med., March 20, 2006; 203(3): 767 - 776. [Abstract] [Full Text] [PDF] W. A. Hassenpflug, U. Budde, T. Obser, D. Angerhaus, E. Drewke, S. Schneppenheim, and R. Schneppenheim Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis Blood, March 15, 2006; 107(6): 2339 - 2345. [Abstract] [Full Text] [PDF] R. Donadelli, J. N. Orje, C. Capoferri, G. Remuzzi, and Z. M. Ruggeri Size regulation of von Willebrand factor-mediated platelet thrombi by ADAMTS13 in flowing blood Blood, March 1, 2006; 107(5): 1943 - 1950. [Abstract] [Full Text] [PDF] S. Zanardelli, J. T. B. Crawley, C. K. N. C. K. Chion, J. K. Lam, R. J. S. Preston, and D. A. Lane ADAMTS13 Substrate Recognition of von Willebrand Factor A2 Domain J. Biol. Chem., January 20, 2006; 281(3): 1555 - 1563. [Abstract] [Full Text] [PDF] T. Ono, J. Mimuro, S. Madoiwa, K. Soejima, Y. Kashiwakura, A. Ishiwata, K. Takano, T. Ohmori, and Y. Sakata Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure Blood, January 15, 2006; 107(2): 528 - 534. [Abstract] [Full Text] [PDF] P. J. Anderson, K. Kokame, and J. E. Sadler Zinc and Calcium Ions Cooperatively Modulate ADAMTS13 Activity J. Biol. Chem., January 13, 2006; 281(2): 850 - 857. [Abstract] [Full Text] [PDF] B. Plaimauer, J. Fuhrmann, G. Mohr, W. Wernhart, K. Bruno, S. Ferrari, C. Konetschny, G. Antoine, M. Rieger, and F. Scheiflinger Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation Blood, January 1, 2006; 107(1): 118 - 125. [Abstract] [Full Text] [PDF] Z. Tao, Y. Peng, L. Nolasco, S. Cal, C. Lopez-Otin, R. Li, J. L. Moake, J. A. Lopez, and J.-f. Dong Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions Blood, December 15, 2005; 106(13): 4139 - 4145. [Abstract] [Full Text] [PDF] J. S. O'Donnell, T. A. J. McKinnon, J. T. B. Crawley, D. A. Lane, and M. A. Laffan Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis Blood, September 15, 2005; 106(6): 1988 - 1991. [Abstract] [Full Text] [PDF] J. Ai, P. Smith, S. Wang, P. Zhang, and X. L. Zheng The Proximal Carboxyl-terminal Domains of ADAMTS13 Determine Substrate Specificity and Are All Required for Cleavage of von Willebrand Factor J. Biol. Chem., August 19, 2005; 280(33): 29428 - 29434. [Abstract] [Full Text] [PDF] G. G. Levy, D. G. Motto, and D. Ginsburg ADAMTS13 turns 3 Blood, July 1, 2005; 106(1): 11 - 17. [Abstract] [Full Text] [PDF] Z. Tao, Y. Wang, H. Choi, A. Bernardo, K. Nishio, J. E. Sadler, J. A. Lopez, and J.-f. Dong Cleavage of ultralarge multimers of von Willebrand factor by C-terminal-truncated mutants of ADAMTS-13 under flow Blood, July 1, 2005; 106(1): 141 - 143. [Abstract] [Full Text] [PDF] R. De Cristofaro, F. Peyvandi, R. Palla, S. Lavoretano, R. Lombardi, G. Merati, F. Romitelli, E. Di Stasio, and P. M. Mannucci Role of Chloride Ions in Modulation of the Interaction between von Willebrand Factor and ADAMTS-13 J. Biol. Chem., June 17, 2005; 280(24): 23295 - 23302. [Abstract] [Full Text] [PDF] E. M. Majerus, P. J. Anderson, and J. E. Sadler Binding of ADAMTS13 to von Willebrand Factor J. Biol. Chem., June 10, 2005; 280(23): 21773 - 21778. [Abstract] [Full Text] [PDF] J. T. B. Crawley, J. K. Lam, J. B. Rance, L. R. Mollica, J. S. O'Donnell, and D. A. Lane Proteolytic inactivation of ADAMTS13 by thrombin and plasmin Blood, February 1, 2005; 105(3): 1085 - 1093. [Abstract] [Full Text] [PDF] J.-D. Studt, J. A. K. Hovinga, G. Antoine, M. Hermann, M. Rieger, F. Scheiflinger, and B. Lammle Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin Blood, January 15, 2005; 105(2): 542 - 544. [Abstract] [Full Text] [PDF] L. B. Ware, M. D. Eisner, B. T. Thompson, P. E. Parsons, and M. A. Matthay Significance of Von Willebrand Factor in Septic and Nonseptic Patients with Acute Lung Injury Am. J. Respir. Crit. Care Med., October 1, 2004; 170(7): 766 - 772. [Abstract] [Full Text] [PDF] T. Uchida, H. Wada, M. Mizutani, M. Iwashita, H. Ishihara, T. Shibano, M. Suzuki, Y. Matsubara, K. Soejima, M. Matsumoto, et al. Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura Blood, October 1, 2004; 104(7): 2081 - 2083. [Abstract] [Full Text] [PDF] K. Nishio, P. J. Anderson, X. L. Zheng, and J. E. Sadler Binding of platelet glycoprotein Ib{alpha} to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13 PNAS, July 20, 2004; 101(29): 10578 - 10583. [Abstract] [Full Text] [PDF] F. Banno, K. Kaminaka, K. Soejima, K. Kokame, and T. Miyata Identification of Strain-specific Variants of Mouse Adamts13 Gene Encoding von Willebrand Factor-cleaving Protease J. Biol. Chem., July 16, 2004; 279(29): 30896 - 30903. [Abstract] [Full Text] [PDF] A. Bernardo, C. Ball, L. Nolasco, J. F. Moake, and J.-f. Dong Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow Blood, July 1, 2004; 104(1): 100 - 106. [Abstract] [Full Text] [PDF] C. Klaus, B. Plaimauer, J.-D. Studt, F. Dorner, B. Lammle, P. M. Mannucci, and F. Scheiflinger Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura Blood, June 15, 2004; 103(12): 4514 - 4519. [Abstract] [Full Text] [PDF] X. L. Zheng, R. M. Kaufman, L. T. Goodnough, and J. E. Sadler Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura Blood, June 1, 2004; 103(11): 4043 - 4049. [Abstract] [Full Text] [PDF] J.-D. Studt, J. A. K. Hovinga, R. Radonic, V. Gasparovic, D. Ivanovic, M. Merkler, U. Wirthmueller, C. Dahinden, M. Furlan, and B. Lammle Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins Blood, June 1, 2004; 103(11): 4195 - 4197. [Abstract] [Full Text] [PDF] J. E. Pimanda, T. Ganderton, A. Maekawa, C. L. Yap, J. Lawler, G. Kershaw, C. N. Chesterman, and P. J. Hogg Role of Thrombospondin-1 in Control of von Willebrand Factor Multimer Size in Mice J. Biol. Chem., May 14, 2004; 279(20): 21439 - 21448. [Abstract] [Full Text] [PDF] A. Padilla, J. L. Moake, A. Bernardo, C. Ball, Y. Wang, M. Arya, L. Nolasco, N. Turner, M. C. Berndt, B. Anvari, et al. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface Blood, March 15, 2004; 103(6): 2150 - 2156. [Abstract] [Full Text] [PDF] M. Matsumoto, K. Kokame, K. Soejima, M. Miura, S. Hayashi, Y. Fujii, A. Iwai, E. Ito, Y. Tsuji, M. Takeda-Shitaka, et al. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome Blood, February 15, 2004; 103(4): 1305 - 1310. [Abstract] [Full Text] [PDF] D. J. Bowen and P. W. Collins An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13 Blood, February 1, 2004; 103(3): 941 - 947. [Abstract] [Full Text] [PDF] K. Kokame, M. Matsumoto, Y. Fujimura, and T. Miyata VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13 Blood, January 15, 2004; 103(2): 607 - 612. [Abstract] [Full Text] [PDF] J. E. Pimanda, A. Maekawa, T. Wind, J. Paxton, C. N. Chesterman, and P. J. Hogg Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13 Blood, January 15, 2004; 103(2): 627 - 629. [Abstract] [Full Text] [PDF] J. E. Sadler, J. L. Moake, T. Miyata, and J. N. George Recent Advances in Thrombotic Thrombocytopenic Purpura Hematology, January 1, 2004; 2004(1): 407 - 423. [Abstract] [Full Text] [PDF] J. Caprioli, F. Castelletti, S. Bucchioni, P. Bettinaglio, E. Bresin, G. Pianetti, S. Gamba, S. Brioschi, E. Daina, G. Remuzzi, et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease Hum. Mol. Genet., December 15, 2003; 12(24): 3385 - 3395. [Abstract] [Full Text] [PDF] E. M. Majerus, X. Zheng, E. A. Tuley, and J. E. Sadler Cleavage of the ADAMTS13 Propeptide Is Not Required for Protease Activity J. Biol. Chem., November 21, 2003; 278(47): 46643 - 46648. [Abstract] [Full Text] [PDF] K. Soejima, M. Matsumoto, K. Kokame, H. Yagi, H. Ishizashi, H. Maeda, C. Nozaki, T. Miyata, Y. Fujimura, and T. Nakagaki ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage Blood, November 1, 2003; 102(9): 3232 - 3237. [Abstract] [Full Text] [PDF] F. Scheiflinger, P. Knobl, B. Trattner, B. Plaimauer, G. Mohr, M. Dockal, F. Dorner, and M. Rieger Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura Blood, November 1, 2003; 102(9): 3241 - 3243. [Abstract] [Full Text] [PDF] J.-f. Dong, J. L. Moake, A. Bernardo, K. Fujikawa, C. Ball, L. Nolasco, J. A. Lopez, and M. A. Cruz ADAMTS-13 Metalloprotease Interacts with the Endothelial Cell-derived Ultra-large von Willebrand Factor J. Biol. Chem., August 8, 2003; 278(32): 29633 - 29639. [Abstract] [Full Text] [PDF] X. Zheng, K. Nishio, E. M. Majerus, and J. E. Sadler Cleavage of von Willebrand Factor Requires the Spacer Domain of the Metalloprotease ADAMTS13 J. Biol. Chem., August 8, 2003; 278(32): 30136 - 30141. [Abstract] [Full Text] [PDF] H.-M. Tsai Advances in the Pathogenesis, Diagnosis, and Treatment of Thrombotic Thrombocytopenic Purpura J. Am. Soc. Nephrol., April 1, 2003; 14(4): 1072 - 1081. [Abstract] [Full Text] [PDF] H.-M. Tsai Platelet Activation and the Formation of the Platelet Plug: Deficiency of ADAMTS13 Causes Thrombotic Thrombocytopenic Purpura Arterioscler Thromb Vasc Biol, March 1, 2003; 23(3): 388 - 396. [Abstract] [Full Text] [PDF] R. Schneppenheim, U. Budde, F. Oyen, D. Angerhaus, V. Aumann, E. Drewke, W. Hassenpflug, J. Haberle, K. Kentouche, E. Kohne, et al. von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP Blood, March 1, 2003; 101(5): 1845 - 1850. [Abstract] [Full Text] [PDF] J.-f. Dong, J. L. Moake, L. Nolasco, A. Bernardo, W. Arceneaux, C. N. Shrimpton, A. J. Schade, L. V. McIntire, K. Fujikawa, and J. A. Lopez ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions Blood, December 1, 2002; 100(12): 4033 - 4039. [Abstract] [Full Text] [PDF] H.-M. Tsai, B. Lammle, V. Bianchi, L. Alberio, M. Furlan, G. Remuzzi, M. Galbusera, and P. M. Mannucci Deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura Blood, November 15, 2002; 100(10): 3839 - 3842. [Full Text] [PDF] B. Plaimauer, K. Zimmermann, D. Volkel, G. Antoine, R. Kerschbaumer, P. Jenab, M. Furlan, H. Gerritsen, B. Lammle, H. P. Schwarz, et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13) Blood, November 15, 2002; 100(10): 3626 - 3632. [Abstract] [Full Text] [PDF] J. E. Sadler A new name in thrombosis, ADAMTS13 PNAS, September 3, 2002; 99(18): 11552 - 11554. [Full Text] [PDF] K. Kokame, M. Matsumoto, K. Soejima, H. Yagi, H. Ishizashi, M. Funato, H. Tamai, M. Konno, K. Kamide, Y. Kawano, et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity PNAS, September 3, 2002; 99(18): 11902 - 11907. [Abstract] [Full Text] [PDF] J. L. Moake Thrombotic Microangiopathies N. Engl. J. Med., August 22, 2002; 347(8): 589 - 600. [Full Text] [PDF] G. Remuzzi, M. Galbusera, M. Noris, M. T. Canciani, E. Daina, E. Bresin, S. Contaretti, J. Caprioli, S. Gamba, P. Ruggenenti, et al. von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome Blood, July 18, 2002; 100(3): 778 - 785. [Abstract] [Full Text] [PDF] V. Bianchi, R. Robles, L. Alberio, M. Furlan, and B. Lammle Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura Blood, June 28, 2002; 100(2): 710 - 713. [Abstract] [Full Text] [PDF] T. J. Raife, S. R. Lentz, B. S. Atkinson, S. K. Vesely, and M. J. Hessner Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity Blood, January 15, 2002; 99(2): 437 - 442. [Abstract] [Full Text] [PDF] J. N. George, J. E. Sadler, and B. Lammle Platelets: Thrombotic Thrombocytopenic Purpura Hematology, January 1, 2002; 2002(1): 315 - 334. [Abstract] [Full Text] P. M. Mannucci, M. T. Canciani, I. Forza, F. Lussana, A. Lattuada, and E. Rossi Changes in health and disease of the metalloprotease that cleaves von Willebrand factor Blood, November 1, 2001; 98(9): 2730 - 2735. [Abstract] [Full Text] [PDF] H. E. Gerritsen, R. Robles, B. Lammle, and M. Furlan Partial amino acid sequence of purified von Willebrand factor-cleaving protease Blood, September 15, 2001; 98(6): 1654 - 1661. [Abstract] [Full Text] [PDF] K. Fujikawa, H. Suzuki, B. McMullen, and D. Chung Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family Blood, September 15, 2001; 98(6): 1662 - 1666. [Abstract] [Full Text] [PDF] A. Veyradier, B. Obert, A. Houllier, D. Meyer, and J.-P. Girma Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases Blood, September 15, 2001; 98(6): 1765 - 1772. [Abstract] [Full Text] [PDF] J. C. Moore, C. P. M. Hayward, T. E. Warkentin, and J. G. Kelton Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders Blood, September 15, 2001; 98(6): 1842 - 1846. [Abstract] [Full Text] [PDF] K. Spring, S. Cross, C. Li, D. Watters, L. Ben-Senior, P. Waring, F. Ahangari, S.-l. Lu, P. Chen, I. Misko, et al. Atm Knock-in Mice Harboring an In-frame Deletion Corresponding to the Human ATM 7636del9 Common Mutation Exhibit a Variant Phenotype Cancer Res., June 1, 2001; 61(11): 4561 - 4568. [Abstract] [Full Text] [PDF] R. Schneppenheim, U. Budde, T. Obser, J. Brassard, K. Mainusch, Z. M. Ruggeri, S. Schneppenheim, R. Schwaab, and J. Oldenburg Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand disease Blood, April 1, 2001; 97(7): 2059 - 2066. [Abstract] [Full Text] [PDF] C. V. Denis, K. Kwack, S. Saffaripour, S. Maganti, P. Andre, R. G. Schaub, and D. D. Wagner Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models Blood, January 15, 2001; 97(2): 465 - 472. [Abstract] [Full Text] [PDF] K. R. McCrae, J. B. Bussel, P. M. Mannucci, G. Remuzzi, and D. B. Cines Platelets: An Update on Diagnosis and Management of Thrombocytopenic Disorders Hematology, January 1, 2001; 2001(1): 282 - 305. [Abstract] [Full Text] [PDF] N. Mistry, S. L. Cranmer, Y. Yuan, P. Mangin, S. M. Dopheide, I. Harper, S. Giuliano, D. E. Dunstan, F. Lanza, H. H. Salem, et al. Cytoskeletal regulation of the platelet glycoprotein Ib/V/IX-von Willebrand factor interaction Blood, November 15, 2000; 96(10): 3480 - 3489. [Abstract] [Full Text] [PDF] F. I. Pareti, A. Lattuada, C. Bressi, M. Zanobini, A. Sala, A. Steffan, and Z. M. Ruggeri Proteolysis of von Willebrand Factor and Shear Stress-Induced Platelet Aggregation in Patients With Aortic Valve Stenosis Circulation, September 12, 2000; 102(11): 1290 - 1295. [Abstract] [Full Text] [PDF] M. Furlan and B. Lammle Haemolytic-uraemic syndrome and thrombotic thrombocytopenic purpura--new insights into underlying biochemical mechanisms Nephrol. Dial. Transplant., August 1, 2000; 15(8): 1112 - 1114. [Full Text] [PDF] S L Allford and S J Machin Current understanding of the pathophysiology of thrombotic thrombocytopenic purpura J. Clin. Pathol., July 1, 2000; 53(7): 497 - 501. [Full Text] [PDF] A. J. Siegel, M. B. Sholar, J. H. Mendelson, S. E. Lukas, M. J. Kaufman, P. F. Renshaw, J. C. McDonald, K. B. Lewandrowski, F. S. Apple, J. J. Stec, et al. Cocaine-Induced Erythrocytosis and Increase in von Willebrand Factor: Evidence for Drug-Related Blood Doping and Prothrombotic Effects Arch Intern Med, September 13, 1999; 159(16): 1925 - 1929. [Abstract] [Full Text] [PDF]

	Copyright © 1996 by American Society of Hematology         Online ISSN: 1528-0020